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Introduction
It has been well established that estrogen deficiency plays
a major role in the pathogenesis of postmenopausal
osteoporosis, which has been attributed to an imbal-
ance in the functions of osteoblasts and osteoclasts
[1,2]. Although the effects of estrogen replacement ther-
apy for the prevention and treatment of osteoporosis
have been confirmed by clinical observations [3–5],
the mechanism by which estrogen interacts with bone
cells remains less clear.
Estrogen exerts its effects on target cells by inter-
acting with specific estrogen receptors (ERs). Following
the cloning of ERα in 1986 [6,7], ERβ was cloned initially
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SUMMARY
Objective: To evaluate the expression of estrogen receptors (ER) α and β, and activity of alkaline phosphatase dur-
ing differentiation of primary osteoblast cells (hOB) from aged postmenopausal women and human osteosarcoma
cell lines (HOS, MG63).
Materials and Methods: Osteoblast cultures were prepared from the upper femur of postmenopausal patients
(age, 60–74 years) and HOS. At the indicated times (days 5, 10, 15, 20, and 25), alkaline phosphatase activity
and expression of ERα and ERβ mRNA were evaluated.
Results: In both cultures of primary hOB and HOS, alkaline phosphatase activity decreased at the osteoblast
proliferation stage, whereas it subsequently increased at the matrix maturation stage. ERβ mRNA was strongly
expressed in HOS on day 15 and remained at high levels of transcription through to day 25 (matrix maturation
phase), whereas ERα mRNA was barely detectable during osteoblast differentiation. In hOB, transcription of
ERα mRNA was much stronger than that of ERβ mRNA.
Conclusion: The presence of ERα and ERβ mRNA in osteoblasts supports the involvement of estrogen in human
bone formation. The developmental expression of alkaline phosphatase was not correlated to ER mRNA expres-
sion during osteoblast differentiation. ER isoforms may have different functions or interact with each other dur-
ing osteoblast differentiation. Since the expression of ER isoforms is different between postmenopausal women
and osteosarcoma cell lines, characteristics of osteosarcoma cell lines may not be suitable as a model for the
evaluation of estrogen effects on postmenopausal osteoporosis. [Taiwanese J Obstet Gynecol 2006;45(4):307–312]
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from rodent and later from human tissues [8–10]. This
finding has raised the question of the relative impor-
tance that ER subtypes have in different target tissues.
In addition, many in vitro studies investigating the effect
of estrogen on osteoblast proliferation and differentia-
tion have produced inconsistent results. The responses
of osteoblast differentiation markers (alkaline phos-
phatase [AP], type I collagen, osteocalcin) to estrogen
have also been shown to vary [11]. The conflicting
responses of osteoblasts to estrogen may, in part, be
attributed to species differences, cellular heterogene-
ity, different stages of differentiation, and/or low or
variable ER content among the various cell lines and
primary cultures.
ERs are present in low numbers in osteoblasts 
in vitro [11,12]. ERα has been reported to be expressed
in murine [13], rat [14], and human sarcoma cell lines
[15–18], as well as in cultured human osteoblast-like
cells [19]. ERβ has also been detected in rat osteoblasts,
a rat osteosarcoma cell line (ROS 17/2.8), cancellous
and cortical bone from 8-week old rats [20], and in
the human osteoblast cell line SV-HFO [21]. Although,
as mentioned above, low levels of ERs in osteoblasts 
in vitro and the effects of estrogen on cells of osteoblast
lineage have been demonstrated, the roles of these
ERs, as well as changes in the osteoblastic phenotype
marker (AP), in osteoblastic differentiation are still
unclear.
This study, therefore, had three main aims. First,
we evaluated changes in AP activity during osteoblast
differentiation and characterized the chronology of cell
differentiation. Second, we investigated the expression
of ERα and ERβ mRNA during human osteoblast dif-
ferentiation. Third, we evaluated whether there were
any correlations between the expression of ERs and AP
activity in human osteoblasts, and whether there were
any differences between primary human osteoblasts and
human osteosarcoma cell lines.
Materials and Methods
Culture of primary human osteoblast-like cells and
established human osteosarcoma cell lines
Human primary osteoblast cells (hOB cells) were
obtained from the upper femur of 16 postmenopausal
patients undergoing bipolar endoprosthesis arthro-
plasty for fractured neck of femur, who had no evidence
of metabolic bone disease. Only tissue that would oth-
erwise be discarded was used, with the approval of the
hospital management committee. All patients were
postmenopausal (age, 60–74 years). None of them had
received any medication, including hormone therapy,
which may have influenced bone metabolism. A human
osteosarcoma cell line (HOS, MG63) was obtained
from the Orthopedic Laboratory of Linko Chang Gung
Memorial Hospital. This study was approved by the
ethical medicine committee of our hospital and sup-
ported by the National Science Council of Taiwan.
First, connective tissue was carefully dissected from
the bone fragments, which were then extensively washed
with phosphate-buffered saline (PBS), diced into small
pieces (3–5 mm in diameter) with a scalpel, and sub-
jected to a 2-hour digestion at 37°C in a shaking water
bath with crude bacterial collagenase at 1 mg/mL in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
Maryland, NY, USA). The fragments were then seeded
into 75-cm2 culture flasks and cultured in a calcium-
free, phenol red-free medium (Gibco) consisting of a
1:1 mixture of penicillin (100 U/mL; Gibco) and strep-
tomycin (100 μg/mL; Gibco). We replaced the medium
with an equal volume (10 mL) of fresh medium every
week during the first 2 weeks and then twice weekly
thereafter. In all cultures, at least 60% of cells showed
intense staining for AP activity.
HOS and passaged primary hOB cells were cultured
in DMEM, at 1:1, with the addition of 10% fetal calf
serum (Gibco), penicillin (100 U/mL; Gibco), strepto-
mycin (100 μg/mL; Gibco), L-glutamine (2 mmol/L;
Gibco), and L-ascorbic acid (100 mg/L; Sigma Chemical
Co., St Louis, MO, USA), in a humidified, 5% CO2
atmosphere at 37°C. The medium was changed every
2–3 days. Cell cultures were monitored by phase con-
trast microscopy for a 25-day period, and cell counts
were performed by Coulter counting in specimens cul-
tured in parallel with the experiments.
AP activity and hOB and HOS cell proliferation 
and differentiation
To measure AP content, primary hOB cells and the HOS
cell line were seeded into 24-well plates at a density 
of 2–3 × 104/cm2 in standard growth medium. At the
indicated times, AP activity was measured after rinsing
the cells twice with PBS, then adding 0.3 mL alkaline
lysis buffer (0.75 M 2-amino-2-methyl-1-propanol; pH
10.3) containing p-nitrophenol phosphate substrate
(2 mg/mL), and incubating this for 30 minutes at
37°C. To stop the reaction, 0.3 mL of 50 mM NaOH
was added to each well. Samples and standards were
diluted in 20mM NaOH, and the absorbance was meas-
ured spectroscopically at 410 nm using an EAR 400
multiwell spectrophotometer (SLT Lab instruments,
Salzburg, Austria). An AP kit was obtained from Sigma
Chemical Co. Cell counts were performed by Coulter
counting, and the data were normalized to represent
AP activity (U/L) per 104 cells for 104 cells.
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Reverse transcription–polymerase chain reaction
analysis of osteoblastic cells
Total RNA was isolated from cells using the single step
guanidinium thiocyanate-phenol-chloroform procedure
described previously by Chomczynski and Sacchi [22]
and quantified spectrophotometrically at 260 nm. One
microgram of total RNA was reverse-transcribed (RT)
into single-strand cDNA with MMLV (Moloney murine
leukemia virus) reverse transcriptase (Epicentre Tech.,
Madison, WI, USA) using 2.5 μM oligo (dT)16 as a
primer. The RT reaction was carried out for 90 minutes
at 37°C in 1X MMLV-RT buffer, 10 mM DTT, and
2.5 mM dNTP. The single-strand cDNA was split into
two aliquots, which were amplified by polymerase chain
reaction (PCR), each in 50-μL reactions with the follow-
ing primers: ERα, 5′-AATTCAGATAATCGACGCCAG-3′
(forward) and 5′-GTGTTTCAACATTCTCCCTCCTC-3′
(reverse); ERβ, 5′-TAGTGGTCCATCGCCAGTTAT-3′ (for-
ward) and 5′-GGGAGCCACACTTCACCAT-3′ (reverse).
The PCR amplifications were carried out with 2 U/μL
Taq DNA polymerase (Promega, Madison, WI, USA),
0.6 μM of each primer, and 0.5 mM dNTP with a cycle
profile of 94°C (denaturing) for 30 seconds, 60°C
(annealing) for 30 seconds, and 72°C (elongation) for
30 seconds. Both ERα and ERβ were PCR-amplified
using 35 cycles to ensure that the PCR reaction was
carried out in the linear portions of the PCR amplifica-
tion. The PCR products were separated by electrophore-
sis on a 1.5% agarose gel and visualized by ethidium
bromide staining.
To construct the internal standards for ERα and
ERβ PCR reactions, pairs of gene-specific primers (as
described above) were inserted into the pBluescript
SK-plasmid at PvuII sites (nt 532 and 977). Therefore,
a 498-bp and a 490-bp fragment could be obtained by
using ERα- and ERβ-specific primers, respectively.
Results
AP activity and characterization of differentiation in
cultures of HOS cells and primary hOB cells
To characterize the differentiation of primary hOB
cells and HOS cells, cellular growth and AP activity
were measured during 25-day cultures. As shown in
Figure 1, HOS cells presented rapid cell proliferation
from day 5 to a maximum on day 15, while primary
hOB cells showed slowly increasing cell growth from
day 5 to day 10 and rapid cell proliferation from day
10 to a maximum on day 15. From day 15 to day 25,
cell proliferation in both primary hOB cells and HOS
cells remained at a plateau. Thus, from the view of cell
growth in the differentiation of both primary hOB cells
and HOS cells, days 5–15 should represent the stage
of rapid cell proliferation. Both primary hOB cells and
HOS cells showed similar patterns of AP activity dur-
ing osteoblast differentiation. As shown in Figure 1,
AP activity had decreased by day 15, and subsequently
increased to a maximum level by day 25. Since AP
activity is an osteoblastic phenotypic marker and rep-
resents bone matrix protein expression, days 15–25
should be the stage of matrix maturation in the differ-
entiation of both primary hOB cells and HOS cells.
Expression of ERa and ERb mRNA in differentiation
of HOS cells and primary hOB cells
To examine the expression of ERα and ERβ mRNA in
human osteoblasts, total RNA was extracted from pri-
mary hOB cell and HOS cell cultures at the indicated
times. A fixed amount of internal standard constructed
for ERα (ISα) or ERβ (ISβ) was added to every RT-PCR
mixture to serve as a base for a more accurate estima-
tion of the levels of ER mRNA. In the culture of pri-
mary hOB cells isolated from the upper femurs of
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Figure 1. Expression of alkaline phosphatase (AP) activity during the differentiation of: (A) primary human osteoblast cells
(hOB); (B) human osteosarcoma cell line (HOS). All results are expressed as the mean from three separate experiments and
are presented as a percentage of maximum expression. Mean values of maximum expression were 282 × 104 cells/mL and
52.5 U AP/L in primary hOB, and 443 × 104 cells/mL and 29.5 U AP/L in HOS.
postmenopausal women, RT-PCR detected a similar
level of high ERα mRNA expression in osteoblast-like
cells cultured during the stages of proliferation and
matrix maturation (Figure 2A), while a very low level of
ERβ mRNA was found in these cells (Figure 2B). A dif-
ferent pattern of ER mRNA expression was found in
the culture of HOS cells compared to primary hOB
cells. In cultures of HOS cells, high levels of ERβ mRNA
appeared on day 15, and its transcriptional activity
was maintained throughout to day 25 (matrix matura-
tion phase) (Figure 3). On the other hand, ERα mRNA
expression during the 25-day culture period was barely
detectable after a 35-cycle PCR. 
Discussion
We have demonstrated that the expression of AP activ-
ity and ER mRNA are non-coordinated during the pro-
liferation of primary hOB cells and a HOS cell line, but
both AP activity and ER mRNA transcription reached
high levels during the matrix maturation stage. In addi-
tion, we also found that during the 25-day osteoblastic
culture, the strength of ERα and ERβ mRNA expres-
sion differed between primary hOB cells and the HOS
cell line. Our data suggest that the expression of ER is
functionally linked to osteoblast maturation, and the
ER isoforms may have different functions or may inter-
act with each other during osteoblast differentiation.
As described by Owen et al [23] for the develop-
ment of fetal rat calvaria cultures, the chronology for
the differentiation of primary hOB cells and HOS cells
is divided into proliferation and extracellular matrix
maturation. In the present study, AP activity decreased
during the stage of proliferation and subsequently
increased to a maximal level during matrix maturation
in both primary hOB cells and the HOS cell line; this is
consistent with results from cultures of hFOB/ER9
cells [24]. The temporal patterns of AP activity by the
HOS cell line and primary hOB cells showed some 
differences from the gene expression in fetal rat cal-
varia cells [23] and primary human osteoblasts [25]. In
those two studies [23,25], the expression of AP mRNA
increased maximally during the maturation stage as in
our report, but did not decrease in the proliferation
stage. Differences in the expression of AP activity may be
attributed to cell proliferative capacity, cellular homo-
geneity, culture conditions used, or different species.
Although the mechanisms by which the skeletal
effects of estrogen are mediated are still obscure, the
importance of ERs in human bone metabolism has
been recognized in several reports. Severely retarded
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Figure 2. Time profile of estrogen receptor (ER) α and ERβ
mRNA expression in primary human osteoblast-like cells ana-
lyzed using reverse transcription–polymerase chain reaction:
(A) ERα; (B) ERβ; (C) β-actin.
Figure 3. Time profile of estrogen receptor (ER) α and ERβ
mRNA expression in human osteosarcoma cell lines ana-
lyzed using reverse transcription–polymerase chain reaction:
(A) ERα; (B) ERβ; (C) β-actin.
skeletal maturation was found in a man with estrogen
resistance due to a mutation in the ERα gene [26],
whereas mice lacking functional ERα were found to
have only minor skeletal abnormalities [27], indicating
that differences between species may influence the role
of ERs in bone development, and that ERα is impor-
tant but is not the only major regulator for normal
bone metabolism. In addition, based on results using
mice with single and double ERα and ERβ knockout
experiments, Windahl et al [28] suggested that ERβ is
involved in both the regulation and maintenance of
cancellous bone in female mice, whereas Sims et al
[29] postulated that ERα was required for normal cor-
tical bone growth in males, although ERβ could com-
pensate for the loss of ERα in females. As discussed
above, the functions of ERs are complex and remain to
be clearly defined. In the present study, we were able
to confirm that the HOS cell line and primary hOB cells
express ERα and ERβ mRNA, but that the strength of
expression of both ERs differs during osteoblast differ-
entiation. These findings further confirm that ERα might
not be the sole mediator of the estrogen response in
bone. ERβ, by itself or in association with ERα, may
also be involved in this process.
In the present study, we demonstrated that ERα
and ERβ are differentially expressed during human
osteoblast differentiation. The present study clearly
demonstrates that ERβ mRNA is highly expressed in an
in vitro differentiating HOS cell line. mRNA expression
of ERβ increased during the stage of proliferation and
further increased up to the moment of maximal activity
of AP (day 25). The results are compatible with those
of a study of human osteoblast SV-HFO cells [21] and
rat bone [20], in which ERβ mRNA expression also
stably increased as cells became more differentiated.
There were some differences in the expression of ERα.
In the present study, ERα mRNA was barely detectable
during HOS cell differentiation. In view of the recent
evidence that ERβ can inhibit ERα activity [30], this
may suggest that one role of ERβ is to modulate ERα
activity, and the relative expression level of the two iso-
forms are related to different cellular conditions as we
found in the differentiation of HOS cells and primary
hOB cells. However, these results suggest that ERβ is
involved in the differentiation of osteoblasts.
The expressions of ERα and ERβ greatly differed in
the culture of primary hOB cells. In the present study,
ERα mRNA expression was more prominent in the pri-
mary hOB cell culture than in the HOS cell line culture.
Since primary hOB cells were obtained from the femoral
neck of aged postmenopausal women (60–74 years old),
it is possible that age or estrogen deficiency is associ-
ated with alteration in the levels or functions of ERs in
bone. This is compatible with the results from Ankrom
et al’s study [31], in which they demonstrated that ERα
levels in osteoblast-like cells are upregulated by an age-
dependent decrease in estrogen. Age-associated diminu-
tion of signal transduction might be a likely mechanism
to explain our observation, in which the increased ERα
mRNA levels might be a consequence of a decreased
ER response reflecting a compensatory mechanism of
the cells. In contrast to ERβ mRNA being highly expressed
during the proliferative and matrix maturation stages
of the HOS cell line, the expression of ERβ mRNA was
less prominent than that of ERα mRNA in the primary
hOB cell culture. In addition to considering aging-
related factors in primary hOB cells, characteristics of
osteosarcoma cell lines might not represent actual
human osteoblast differentiation. Furthermore, a study
by Hall and McDonnell [30] showed that tamoxifen
functioned as an agonist when ERα alone was expressed
in a cell and showed no agonist activity when ERβ
alone was expressed. This suggests that it is important
to determine the extent to which the two receptors co-
localize in order to more accurately predict the biolog-
ical responses to ER agonists in specific target tissues.
Thus, the differential expressions of ERα and ERβ
mRNA in osteoblast differentiation suggest the possi-
bility that ERα and ERβ may act in conjunction with
each other, as well as affect the response to estrogen.
It remains to be determined to what extent the ratio of
ERα and ERβ expression in osteoblasts is species- or
age-dependent, or if they are differentially expressed at
various skeletal sites.
In conclusion, the presence of both ERα and ERβ
mRNA in osteoblasts further supports the involvement
of the estrogen endocrine system in human bone for-
mation. Differential regulation of the expression of ER
isoforms during osteoblast differentiation suggests that
they may have different functions or that they may inter-
act with each other. Obviously, the next essential step
is to investigate how the ratio of ERα and ERβ expres-
sion determines the downstream activity of estrogen in
bone. In addition, since the expression of ER isoforms
is different between postmenopausal women and osteo-
sarcoma cell lines, characteristics of osteosarcoma cell
lines may not be suitable as a model for the study of
actual human osteoblast differentiation, especially in the
evaluation of the effects of estrogen on postmenopausal
osteoporosis.
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